Bulletin of Pharmacy Practice
Content Available at www.lapinpress.com ISSN (O): 3139-9444
(An online peer reviewed Referred Journal)
Review Article
OPEN ACCESS

APPLICATIONS OF PHARMACOEPIDEMIOLOGY IN DRUG SAFETY SURVEILLANCE AND PUBLIC HEALTH DECISION-MAKING: A NARRATIVE REVIEW

SADHANA KANUKUNTLA

Assistant Professor, Department of Pharmacy Practice, School of Pharmacy, Anurag University, Venkatapur, Ghatkesar, Medchal, Hyderabad, Telangana, India – 500 088.

***Corresponding Author**
Dr. Sadhana Kanukuntla

Article History: Received: 19 March 2026, Revised: 02 April 2026, Accepted: 26 April 2026

Abstract: Pharmacoepidemiology, the scientific discipline that integrates principles of pharmacology and epidemiology, plays a critical role in evaluating the use, effectiveness, safety, and outcomes of medications in real-world populations. While pre-marketing clinical trials provide essential evidence regarding drug efficacy and short-term safety, they often involve selected populations, limited sample sizes, and restricted follow-up periods, which may not adequately identify rare, delayed, or population-specific adverse events. Consequently, pharmacoepidemiological studies have become indispensable for post-marketing drug safety surveillance and evidence-based public health decision-making. This narrative review examines the applications of pharmacoepidemiology in pharmacovigilance, adverse drug reaction detection, risk assessment, comparative effectiveness research, drug utilization evaluation, and healthcare policy development. Various study designs used in pharmacoepidemiology, including cohort studies, case-control studies, cross-sectional studies, self-controlled methods, and analyses based on electronic healthcare databases, are discussed. The review highlights the role of real-world evidence, large healthcare datasets, artificial intelligence, and data-linkage systems in enhancing drug safety surveillance. Furthermore, the contributions of pharmacoepidemiological evidence to regulatory decision-making, health technology assessment, and public health interventions are explored through contemporary examples.

Despite significant advances, challenges such as data quality issues, confounding, privacy concerns, underreporting of adverse drug reactions, and methodological limitations persist. Strengthening international collaboration, improving data interoperability, and integrating advanced analytical approaches will further enhance the value of pharmacoepidemiology in optimizing medication safety and supporting informed public health policies.

Keywords: *Pharmacoepidemiology; Drug safety; Pharmacovigilance; Real-world evidence; Public health; Adverse drug reactions*

This article is licensed under a Creative Commons Attribution-Non-commercial 4.0 International License.
Copyright © 2026 Author(s) retains the copyright of this article.

1. INTRODUCTION

Medicines are among the most effective interventions for preventing and treating diseases; however, their use may also result in unintended adverse effects that significantly impact patient outcomes and healthcare systems [1]. Although randomized controlled trials (RCTs) remain the gold standard for evaluating drug efficacy and initial safety, they often have limited external validity due to strict inclusion criteria, relatively short follow-up periods, and insufficient power to detect rare adverse events [2].

The increasing complexity of healthcare systems, widespread use of medications, aging populations, and rising prevalence of chronic diseases have amplified the need for continuous monitoring of medication safety in real-world settings [3]. Pharmacoepidemiology has emerged as a critical discipline that bridges the gap between clinical pharmacology and epidemiology by examining the use and effects of medications in large populations [4].

The field gained prominence following several historical drug safety crises, including the thalidomide tragedy in the 1960s, cardiovascular risks associated with rofecoxib, and safety concerns surrounding certain antidiabetic and antidepressant medications [5]. These events highlighted the limitations of pre-marketing clinical trials and emphasized the need for robust post-marketing surveillance systems.

Pharmacoepidemiology contributes substantially to pharmacovigilance, risk management, comparative effectiveness research, health technology assessment, and public health policy development [6]. By utilizing observational study designs and large healthcare databases, pharmacoepidemiologists generate real-world evidence (RWE) that informs regulatory actions and clinical practice.

This narrative review explores the principles, methodologies, applications, challenges, and future directions of pharmacoepidemiology in drug safety surveillance and public health decision-making.

2. CONCEPT AND SCOPE OF PHARMACOEPIDEMIOLOGY

Pharmacoepidemiology is defined as the study of the use and effects of medications in large populations by applying epidemiological methods to pharmacological research [7].

The discipline aims to:

- Evaluate medication utilization patterns
- Detect and quantify adverse drug reactions (ADRs)
- Assess medication effectiveness in routine practice
- Identify risk factors associated with drug-related harm
- Support evidence-based healthcare decisions
- Inform regulatory and policy actions

Pharmacoepidemiology encompasses both descriptive and analytical approaches and relies heavily on real-world data sources.

Table 01: Major Objectives and Applications of Pharmacoepidemiology

Objective	Description	Public Health Relevance
Drug utilization research	Evaluation of prescribing and medication use patterns	Promotes rational medicine use
Pharmacovigilance	Detection and assessment of adverse drug reactions	Improves medication safety
Comparative effectiveness research	Comparison of treatment outcomes in real-world settings	Supports clinical decision-making
Risk-benefit assessment	Evaluation of therapeutic benefits versus potential risks	Informs regulatory actions
Health technology assessment	Assessment of clinical and economic value	Guides reimbursement decisions
Policy development	Generation of evidence for healthcare policies	Enhances population health outcomes

As shown in Table 01, pharmacoepidemiology supports multiple aspects of healthcare delivery and public health decision-making.

3. DATA SOURCES IN PHARMACOEPIDEMIOLOGY

The availability of large-scale healthcare databases has transformed pharmacoepidemiological research.

Common data sources include:

- Electronic health records (EHRs)
- Administrative claims databases
- Disease registries
- Spontaneous reporting systems
- Prescription databases
- National health surveys
- Biobanks
- Patient-reported outcomes databases

Each data source offers unique strengths and limitations regarding completeness, timeliness, and generalizability [8].

Figure 01: Common Data Sources Used in Pharmacoepidemiology

4. STUDY DESIGNS IN PHARMACOEPIDEMIOLOGY

Observational study designs form the methodological foundation of pharmacoepidemiology.

4.1 Cohort Studies

Cohort studies compare outcomes among exposed and unexposed populations over time [9].

Advantages include:

- Ability to estimate incidence rates
- Assessment of multiple outcomes
- Clear temporal relationship

However, cohort studies may be resource-intensive and susceptible to confounding.

4.2 Case-Control Studies

Case-control studies compare prior medication exposures between patients with and without specific outcomes [10]. These studies are particularly useful for evaluating rare adverse events.

4.3 Cross-Sectional Studies

Cross-sectional studies assess exposure and outcomes simultaneously, providing information about prevalence and medication utilization patterns [11].

4.4 Self-Controlled Designs

Self-controlled case series and case-crossover studies use individuals as their own controls, minimizing confounding by stable patient characteristics [12].

4.5 Ecological Studies

Ecological studies examine relationships between medication use and health outcomes at population levels.

Table 02: Common Study Designs in Pharmacoepidemiology

Study Design	Primary Purpose	Strengths	Limitations
Cohort study	Evaluate incidence and risk	Temporal relationship, multiple outcomes	Confounding, resource intensive
Case-control study	Investigate rare outcomes	Efficient and cost-effective	Recall and selection bias
Cross-sectional study	Assess prevalence	Rapid and inexpensive	Cannot establish causality
Self-controlled case series	Evaluate transient exposures	Controls for fixed confounders	Requires precise timing data
Ecological study	Assess population-level associations	Useful for policy evaluation	Ecological fallacy

As summarized in Table 02, the choice of study design depends on the research question, available data sources, and outcome characteristics.

5. PHARMACOEPIDEMIOLOGY IN DRUG SAFETY SURVEILLANCE

Drug safety surveillance involves the continuous monitoring, assessment, and prevention of adverse effects associated with medications [13].

5.1 Pharmacovigilance

Pharmacovigilance refers to the science and activities related to detecting, assessing, understanding, and preventing adverse effects or other medicine-related problems [14].

Pharmacoepidemiological methods enhance pharmacovigilance by:

- Identifying safety signals
- Quantifying risks
- Evaluating causal relationships
- Monitoring risk minimization strategies

5.2 Signal Detection and Validation

Safety signals are information suggesting a possible causal association between a drug and an adverse event [15].

Signal detection methods include:

- Disproportionality analysis
- Data mining algorithms
- Bayesian approaches
- Machine learning techniques

5.3 Risk Assessment and Quantification

Pharmacoepidemiological studies estimate:

- Relative risk
- Odds ratio

- Hazard ratio
- Absolute risk difference

These measures assist regulators and clinicians in evaluating medication safety profiles.

5.4 Post-Marketing Surveillance

Post-marketing surveillance addresses limitations of pre-approval clinical trials by examining medication safety in broader populations [16].

6. REAL-WORLD EVIDENCE AND REGULATORY DECISION-MAKING

Real-world evidence (RWE) is derived from the analysis of real-world data collected outside traditional clinical trials [17].

Regulatory agencies increasingly utilize RWE to support:

- Label modifications
- Post-authorization safety studies
- Risk management plans
- Market withdrawal decisions

Examples of major regulatory organizations include:

- World Health Organization
- United States Food and Drug Administration
- European Medicines Agency

The withdrawal of rofecoxib due to increased cardiovascular risk demonstrates the importance of pharmacoepidemiological evidence in regulatory decision-making [18].

7. APPLICATIONS IN PUBLIC HEALTH DECISION-MAKING

Pharmacoepidemiological evidence informs multiple public health activities.

7.1 Drug Utilization Evaluation

Drug utilization studies identify:

- Prescribing trends
- Polypharmacy patterns
- Irrational medication use
- Medication adherence issues [19]

7.2 Health Technology Assessment

Health technology assessment (HTA) integrates clinical, economic, social, and ethical considerations to inform reimbursement decisions [20].

7.3 Vaccine Safety Monitoring

Pharmacoepidemiological methods have played a crucial role in evaluating vaccine safety during large-scale immunization programs [21].

7.4 Pandemic Preparedness and Response

The COVID-19 pandemic highlighted the importance of real-world evidence in evaluating medication effectiveness and vaccine safety [22].

7.5 Addressing Health Inequities

Pharmacoepidemiology can identify disparities in medication access, utilization, and outcomes among vulnerable populations [23].

Table 03: Applications of Pharmacoepidemiology in Public Health Decision-Making

Public Health Domain	Pharmacoepidemiological Application	Expected Outcome
Pharmacovigilance	Adverse drug reaction monitoring	Enhanced medication safety
Drug utilization research	Evaluation of prescribing patterns	Rational medicine use
Health technology assessment	Cost-effectiveness evaluation	Evidence-based reimbursement
Vaccine safety	Monitoring adverse events following immunization	Increased public confidence
Pandemic response	Assessment of treatment effectiveness	Improved emergency preparedness
Health equity	Identification of disparities in medicine use	Targeted interventions

As outlined in Table 03, pharmacoepidemiology contributes to diverse public health initiatives and policy decisions.

8. EMERGING TECHNOLOGIES AND INNOVATIONS

Technological advancements are reshaping pharmacoepidemiological research.

8.1 Big Data Analytics

Large-scale datasets enable the evaluation of rare adverse events and long-term outcomes [24].

8.2 Artificial Intelligence and Machine Learning

Artificial intelligence enhances:

- Signal detection
- Pattern recognition
- Predictive modeling
- Automated data extraction [25]

8.3 Data Linkage Systems

Linking multiple healthcare databases improves data completeness and validity [26].

8.4 Pharmacogenomics

Integration of genetic information supports precision medicine and individualized risk assessment [27].

8.5 Digital Health Technologies

Wearable devices, mobile applications, and remote monitoring systems generate valuable real-world data [28].

9. CHALLENGES AND LIMITATIONS

Despite significant advances, several challenges remain.

9.1 Data Quality Issues

Incomplete or inaccurate data may compromise study validity [29].

9.2 Confounding and Bias

Observational studies are susceptible to:

- Confounding by indication
- Selection bias
- Information bias
- Misclassification bias

9.3 Underreporting of Adverse Drug Reactions

Spontaneous reporting systems often capture only a fraction of actual adverse events [30].

9.4 Privacy and Ethical Concerns

The use of large healthcare datasets raises concerns regarding:

- Data security
- Patient confidentiality
- Informed consent

9.5 Methodological Complexity

Advanced analytical techniques require specialized expertise and robust infrastructure.

10. FUTURE DIRECTIONS

Future developments in pharmacoepidemiology are expected to include:

- Greater integration of artificial intelligence
- Expansion of international data-sharing networks
- Standardization of real-world data collection
- Improved interoperability among healthcare systems
- Increased use of patient-generated health data
- Integration of pharmacogenomic information
- Enhanced transparency and reproducibility

Strengthening collaborations among regulators, researchers, healthcare providers, and industry stakeholders will further enhance drug safety surveillance and public health outcomes [31].

11. CONCLUSION

Pharmacoepidemiology has become an essential component of modern healthcare systems by providing robust evidence regarding medication use, effectiveness, and safety in real-world populations. Through the application of observational research methods and analysis of large healthcare datasets, pharmacoepidemiology addresses critical gaps left by pre-marketing clinical trials.

The discipline plays a central role in pharmacovigilance, signal detection, post-marketing surveillance, comparative effectiveness research, and public health policy development. Real-world evidence generated through pharmacoepidemiological studies increasingly informs regulatory decisions, health technology assessments, and healthcare resource allocation.

Emerging technologies such as artificial intelligence, big data analytics, pharmacogenomics, and digital health platforms offer significant opportunities to enhance drug safety surveillance and improve population health outcomes. However, challenges related to data quality, confounding, privacy, and methodological limitations must be addressed to maximize the utility of pharmacoepidemiological research.

Continued investment in data infrastructure, international collaboration, and advanced analytical methodologies will strengthen the contribution of pharmacoepidemiology to evidence-based public health decision-making and ensure safer, more effective use of medicines worldwide.

12. FUNDING

Nil

13. ACKNOWLEDGEMENT

Not Declared.

14. CONFLICT OF INTEREST

Nil

15. INFORMED CONSENT

Not applicable

16. ETHICAL STATEMENT

Not Applicable.

17. REFERENCES

1. World Health Organization. Medication without harm: global patient safety challenge on medication safety. Geneva: WHO; 2017.
2. Rothwell PM. External validity of randomised controlled trials: "to whom do the results of this trial apply?" Lancet. 2005;365(9453):82–93.
3. Marengoni A, Angleman S, Melis R, Mangialasche F, Karp A, Garmen A, et al. Aging with multimorbidity: a systematic review of the literature. Ageing Res Rev. 2011;10(4):430–9.
4. Strom BL, Kimmel SE, Hennessy S, editors. Textbook of Pharmacoepidemiology. 3rd ed. Chichester: Wiley-Blackwell; 2019.
5. McBride WG. Thalidomide and congenital abnormalities. Lancet. 1961;278(7216):1358.
6. Hartzema AG, Tilson HH, Chan KA. Pharmacoepidemiology and therapeutic risk management. Cincinnati: Harvey Whitney Books; 2008.
7. Strom BL. What is pharmacoepidemiology? In: Strom BL, Kimmel SE, Hennessy S, editors. Textbook of Pharmacoepidemiology. 3rd ed. Chichester: Wiley-Blackwell; 2019. p. 3–12.
8. Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research. J Clin Epidemiol. 2005;58(4):323–37.
9. Grimes DA, Schulz KF. Cohort studies: marching towards outcomes. Lancet. 2002;359(9303):341–5.
10. Grimes DA, Schulz KF. Compared to what? Finding controls for case-control studies. Lancet. 2005;365(9468):1429–33.
11. Levin KA. Study design III: cross-sectional studies. Evid Based Dent. 2006;7(1):24–5.
12. Whitaker HJ, Farrington CP, Spiessens B, Musonda P. Tutorial in biostatistics: the self-controlled case series method. Stat Med. 2006;25(10):1768–97.
13. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356(9237):1255–9.
14. World Health Organization. The importance of pharmacovigilance: safety monitoring of medicinal products. Geneva: WHO; 2002.
15. Hauben M, Zhou X. Quantitative methods in pharmacovigilance. Drug Saf. 2003;26(3):159–86.
16. Giezen TJ, Mantel-Teeuwisse AK, Straus SM, Schellekens H, Leufkens HG, Egberts AC. Safety-related regulatory actions for biologicals approved in the United States and the European Union. JAMA. 2008;300(16):1887–96.
17. Sherman RE, Anderson SA, Dal Pan GJ, Gray GW, Gross T, Hunter NL, et al. Real-world evidence—what is it and what can it tell us? N Engl J Med. 2016;375(23):2293–7.
18. Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G, et al. Risk of acute myocardial infarction and sudden cardiac death associated with cyclooxygenase-2 selective and non-selective NSAIDs. Lancet. 2005;365(9458):475–81.

19. Wettermark B, Elseviers M, Almarsdóttir AB, Andersen M, Benko R, Bennie M, et al. Introduction to drug utilization research. In: Drug Utilization Research: Methods and Applications. Chichester: Wiley-Blackwell; 2016. p. 3–12.
20. Drummond MF, Schwartz JS, Jönsson B, Luce BR, Neumann PJ, Siebert U, et al. Key principles for the improved conduct of health technology assessments. Value Health. 2008;11(4):732–45.
21. Black S, Eskola J, Siegrist CA, Halsey N, MacDonald N, Law B, et al. Importance of background rates of disease in assessing vaccine safety. Vaccine. 2009;27(16):2114–9.
22. Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA COVID-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021;384(15):1412–23.
23. Arcaya MC, Arcaya AL, Subramanian SV. Inequalities in health: definitions, concepts, and theories. Glob Health Action. 2015;8:27106.
24. Jensen PB, Jensen LJ, Brunak S. Mining electronic health records. Nat Rev Genet. 2012;13(6):395–405.
25. Harpaz R, DuMouchel W, Shah NH, Madigan D, Ryan P, Friedman C. Novel data-mining methodologies for adverse drug event discovery. Clin Pharmacol Ther. 2012;91(6):1010–21.
26. Harron K, Dibben C, Boyd J, Hjern A, Azimaee M, Barreto ML, et al. Challenges in administrative data linkage for research. Big Data Soc. 2017;4(2):1–12.
27. Relling MV, Evans WE. Pharmacogenomics in the clinic. Nature. 2015;526(7573):343–50.
28. Coravos A, Goldsack JC, Karlin DR, Nebeker C, Perakslis E, Zimmerman N, et al. Digital medicine. NPJ Digit Med. 2019;2:31.
29. Weiskopf NG, Weng C. Methods and dimensions of electronic health record data quality assessment. J Am Med Inform Assoc. 2013;20(1):144–51.
30. Hazell L, Shakir SA. Under-reporting of adverse drug reactions. Drug Saf. 2006;29(5):385–96.
31. Franklin JM, Schneeweiss S. When and how can real world data analyses substitute for randomized controlled trials? Clin Pharmacol Ther. 2017;102(6):924–33.